[Current status and prospect of neoplasm targeted therapy].
Wang
Yan
Y
Department of Internal Medicine, Oncology Hospital, Institute of Oncology, China Union Medical University, Chinese Academy of Medical Sciences, Beijing 100021, China
Sun
Yan
Y
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D000068818:Cetuximab; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D007155:Immunologic Factors; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D000077156:Gefitinib